* Alnylam Pharmaceuticals Inc is expected to show a rise in quarterly revenue when it reports results on May 2 for the period ending March 31 2024
* The Cambridge Massachusetts-based company is expected to report a 33.8% increase in revenue to $427.329 million from $319.29 million a year ago, according to the mean estimate from 22 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Alnylam Pharmaceuticals Inc is for a loss of $1.18 per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy," 9 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by about 1.6% in the last three months.
* Wall Street's median 12-month price target for Alnylam Pharmaceuticals Inc is $221.00, above its last closing price of $147.36.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -1.46 -1.32 -1.10 Beat 16.8
Sep. 30 0001 -1.26 -1.34 1.15 Beat 186.1
Jun. 30 2023 -1.50 -1.37 -2.21 Missed -61.5
Mar. 31 2023 -1.79 -1.77 -1.40 Beat 20.7
Jan. -1.95 -1.87 -1.68 Beat 10.3
1 0001
Sep. 30 2022 -1.79 -1.74 -2.69 Missed -54.5
Jun. 30 2022 -1.63 -1.63 -2.29 Missed -40.5
Mar. 31 2022 -1.85 -1.84 -2.00 Missed -8.7
This summary was machine generated April 30 at 16:23 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments